TY - JOUR
T1 - Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation
AU - Chelariu-Raicu, Anca
AU - Piha-Paul, Sarina A.
AU - Chavez-Macgregor, Mariana
AU - Johnson, Jason
AU - Sawaya, Raymond
AU - McAleer, Mary Frances
AU - Nguyen, Alissa
AU - Hartnett, Audrey
AU - Tsimberidou, Apostolia M.
AU - Meric-Bernstam, Funda
AU - Dumbrava, Ecaterina E.
N1 - Publisher Copyright:
© 2023, Innovative Healthcare Institute. All rights reserved.
PY - 2023/8
Y1 - 2023/8
N2 - Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except for BRCA1/2 mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, there is inadequate identification of predictive biomarkers of response. We present a 57-year-old woman with metastatic breast cancer, hormone-receptor-positive, HER2 negative with a germline ataxia-telangiectasia mutation with a large brain metastasis with clinical benefit to talazoparib. This case report exemplifies the importance of the multidisciplinary management of patients with brain metastases and personalized biomarker selected treatment.
AB - Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except for BRCA1/2 mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, there is inadequate identification of predictive biomarkers of response. We present a 57-year-old woman with metastatic breast cancer, hormone-receptor-positive, HER2 negative with a germline ataxia-telangiectasia mutation with a large brain metastasis with clinical benefit to talazoparib. This case report exemplifies the importance of the multidisciplinary management of patients with brain metastases and personalized biomarker selected treatment.
KW - ataxia-telangiectasia mutation (ATM)
KW - brain metastasis
KW - breast cancer
KW - PARPi
KW - precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85168608728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85168608728&partnerID=8YFLogxK
U2 - 10.36401/JIPO-22-33
DO - 10.36401/JIPO-22-33
M3 - Article
C2 - 37637237
AN - SCOPUS:85168608728
SN - 2666-2345
VL - 6
SP - 158
EP - 161
JO - Journal of Immunotherapy and Precision Oncology
JF - Journal of Immunotherapy and Precision Oncology
IS - 3
ER -